Lv6
2310 积分 2021-04-14 加入
Advantages of Robotic-assisted Thoracic Surgery after Neoadjuvant Therapy in NSCLC: A Propensity Score–matched Analysis
2个月前
已完结
Exploring clinical factors to predict the survival for resectable non-small cell lung cancer patients with neoadjuvant immunotherapy
3个月前
已完结
Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Resectable Non–small Cell Lung Cancer Treated With Neoadjuvant Immunotherapy Plus Chemotherapy
3个月前
已完结
An all-in-one polymeric nanomedicine as in situ cascade cancer vaccine for potent cancer immunotherapy
3个月前
已完结
Facts and hopes in neoadjuvant immunotherapy combinations in resectable non-small-cell lung cancer
5个月前
已完结
Efficacy, Safety, and Influence on Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1 Positive NSCLC: A Phase 2 Trial (EAST ENERGY)
6个月前
已完结
[Guidelines on clinical practice of molecular tests in non-small cell lung cancer in China (2024 version)]
6个月前
已完结
Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial
6个月前
已完结
Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial
6个月前
已完结
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
6个月前
已完结
皖公网安备34019202002308
